Literature DB >> 19024325

[Multiparametric flow cytometry analyzes the expressions of immunophenotype CD133, CD34, CD44 in lung cancer naive cells].

Dan Liu1, Wei-min Li, Xian-ming Mo, Lun-xu Liu, Yun Wang, Guo-wei Che, Zhu Wu, Ji-long Gou.   

Abstract

OBJECTIVE: To study the expression of CD133, CD34 and CD44 in lung cancer, and distribution of cell subpopulations that generated by combination of different markers.
METHODS: By collecting 10 normal lung tissues and 40 lung cancer fresh samples that were diagnosed pathologically, preparing single cell suspension, and labelling cells with CD133, CD34, CD44, CD117, CD43, CD45 and LIN(CD2, CD3, CD31, CD64) monoclone antibodies, we analyzed the distribution of the above-mentioned antibodies in lung cancer cells on FCM. By double-parameters plots, we analyzed the naive cell subpopulations that were generated through combination of positive and negative antigen expression.
RESULTS: In lung cancer parenchymal-cells (LIN- CD45-) expressed CD133, CD34 and CD44 dim positive and, expressed CD117 and CD43 negative. The mann-Whitney rank test results shows that there was no significant difference for the expression of CD133, CD34, CD44 between lung cancer and normal lung tissue, and CD44+, CD133- CD34-, CD133+ CD44+, CD133+ CD44-, CD133+ CD34+, CD133- CD34+ and CD133- CD44+ expressed differently (P < 0.05) between lung adenocarcinoma and lung squamous cell carcinoma. The cluster analysis results suggest that they are classified to 4 subsets.
CONCLUSION: CD133, CD34, CD44 could be the marker of lung cancer naive cells, which could contribute to study lung cancer cell development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19024325

Source DB:  PubMed          Journal:  Sichuan Da Xue Xue Bao Yi Xue Ban        ISSN: 1672-173X


  1 in total

1.  Interferon-induced transmembrane protein 1-mediated EGFR/SOX2 signaling axis is essential for progression of non-small cell lung cancer.

Authors:  Ying-Gui Yang; Young Wha Koh; Ita Novita Sari; Nayoung Jun; Sanghyun Lee; Lan Thi Hanh Phi; Kwang Seock Kim; Yoseph Toni Wijaya; Sang Hun Lee; Moo-Jun Baek; Dongjun Jeong; Hyog Young Kwon
Journal:  Int J Cancer       Date:  2018-12-08       Impact factor: 7.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.